Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK4381406 in Healthy Participants
NCT05999708Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTL0027477 in ulcerative colitis (UC) (8 arms), sponsored by GSK. Primary endpoints: Number of participants with adverse events (AEs) and serious adverse events (SAEs), Number of participants with clinically significant changes in hematology laboratory values and 4 more. Planned start Oct 2023; status: withdrawn.
02
Drugs
HTL0027477
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05999708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999708.